Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD4901 (oral)
AZD4901 · 1 trial · 1 indication
Change-from-baseline of luteinising hormone area under the concentration-time curve from time zero to 8 hours postdose \[AUC(0-8)\] at Day 7
| Arm | Type | Description |
|---|---|---|
| AZD4901 20 mg once a day | EXPERIMENTAL | AZD4901 20 mg once a day |
| AZD4901 20mg twice a day | EXPERIMENTAL | AZD4901 20mg twice a day |
| AZD4901 40 mg twice a day | EXPERIMENTAL | AZD4901 40 mg twice a day |
| Placebo to match AZD4901 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AZD4901 (oral) | DRUG | Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo |
| Placebo to match AZD4901 | DRUG | Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo |
Inclusion Criteria: Female patients between the ages of 18 to 45 years (inclusive). Suitable veins for cannulation or repeated venipuncture. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive). A diagnosis of polycystic ovary disease. Amenorrhea or oligomenorrhea (defined as ≤ 6 menses per ye...
AZD4901 is an investigational small molecule being studied for Polycystic Ovary Syndrome (PCOS) and female endocrine disorders. It has been evaluated in a Phase 2 clinical trial in women with PCOS. It is not approved for any indication and remains in clinical development.
AZD4901 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company sponsored the Phase 2 study of the drug in women with Polycystic Ovary Syndrome.
AZD4901 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved for marketing in any indication.
AZD4901 has been studied in one completed Phase 2 trial, NCT01872078, titled A Study of AZD4901 in Females With Polycystic Ovary Syndrome. The trial enrolled 67 female participants aged 18 years and older across the United States, Germany, and the United Kingdom.
Yes, AZD4901 (oral) is an alternative name for AZD4901. Both refer to the same investigational small molecule developed by AstraZeneca for Polycystic Ovary Syndrome and female endocrine disorders.